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Shinichiro Ueda15, Teruo Inoue16, Toyoaki Murohara14, Koichi Node1* and On behalf of the PRIZE Study 
Investigators
Abstract 
Background: Xanthine oxidase inhibitors are anti‑hyperuricemic drugs that decrease serum uric acid levels by inhib‑
iting its synthesis. Xanthine oxidase is also recognized as a pivotal enzyme in the production of oxidative stress. Excess 
oxidative stress induces endothelial dysfunction and inflammatory reactions in vascular systems, leading to athero‑
sclerosis. Many experimental studies have suggested that xanthine oxidase inhibitors have anti‑atherosclerotic effects 
by decreasing in vitro and in vivo oxidative stress. However, there is only limited evidence on the clinical implications 
of xanthine oxidase inhibitors on atherosclerotic cardiovascular disease in patients with hyperuricemia. We designed 
the PRIZE study to evaluate the effects of febuxostat on a surrogate marker of cardiovascular disease risk, ultrasonog‑
raphy‑based intima‑media thickness of the carotid artery in patients with hyperuricemia.
Methods: The study is a multicenter, prospective, randomized, open‑label and blinded‑endpoint evaluation (PROBE) 
design. A total of 500 patients with asymptomatic hyperuricemia (uric acid >7.0 mg/dL) and carotid intima‑media 
thickness ≥1.1 mm will be randomized centrally to receive either febuxostat (10–60 mg/day) or non‑pharmacological 
treatment. Randomization is carried out using the dynamic allocation method stratified according to age (<65, 
≥65 year), gender, presence or absence of diabetes mellitus, serum uric acid (<8.0, ≥8.0 mg/dL), and carotid intima‑
media thickness (<1.3, ≥1.3 mm). In addition to administering the study drug, we will also direct lifestyle modification 
in all participants, including advice on control of body weight, sleep, exercise and healthy diet. Carotid intima‑media 
thickness will be evaluated using ultrasonography performed by skilled technicians at a central laboratory. Follow‑up 
will be continued for 24 months. The primary endpoint is percentage change in mean intima‑media thickness of the 
common carotid artery 24 months after baseline, measured by carotid ultrasound imaging.
Conclusions: PRIZE will be the first study to provide important data on the effects of febuxostat on atherosclerosis in 
patients with asymptomatic hyperuricemia.
© 2016 The Author(s). This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
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Background
Uric acid (UA) is an end product of the purine meta-
bolic pathway catalyzed by xanthine oxidase (XO), with 
increased levels of UA associated closely with various 
pathophysiologies [1, 2]. Evidence from clinical stud-
ies has suggested that hyperuricemia is associated with 
the characteristics of the metabolic syndrome (MetS), 
including obesity, hypertension (HT), hyperlipidemia 
(HL), diabetes mellitus (DM) [3–7], and cardiovascular 
disease (CVD) [8–11]. Takayama et  al. [12] showed in 
both males and females without the MetS that hyper-
uricemia is an independent risk factor for the incidence 
of carotid atherosclerosis imaged by ultrasound. Kawa-
moto et al. [13] also demonstrated that the prevalence of 
the MetS increased according to serum UA levels only in 
women and in men without the Mets, suggesting that UA 
levels were an independent risk factor of carotid athero-
sclerosis. Although UA is considered to be a risk factor or 
marker for CVD [14, 15], there is still some controversy 
regarding its independent contribution to CVD risk. For 
example, it has been reported that there is no relation-
ship between UA levels and the increased risk of death 
from all causes, including CVD and stroke in Japanese 
people aged ≥30 years [16].
Although the mechanisms for the effects of hyperurice-
mia on atherosclerosis remain uncertain [17, 18], possible 
pathophysiological actions may include several adverse 
effects on endothelial dysfunction, oxidative metabolism, 
inflammation, and platelet adhesiveness and aggregation 
[19–22]. The mediators and cytokines produced by these 
processes interact with background pathology such as 
the MetS and insulin resistance, leading to cellular dam-
age. Recent studies in animal models report that UA may 
have a causal role in the development of atherosclerosis, 
whereas lowering uric acid levels prevented or reversed 
the features of the MetS [23].
Febuxostat, a novel non-purine selective inhibi-
tor of XO was developed 40 years ago and was the first 
XO inhibitor with stronger UA-lowering effects [24]. 
Compared to allopurinol, a conventional XO inhibitor, 
febuxostat can be administered to patients with mild 
to moderately impaired renal function because of its 
dual excretion pathway [24]. Recent reports support the 
effectiveness of febuxostat in the treatment of patients 
with gout [25, 26]. Febuxostat is now used widely in 
hyperuricemia patients both with and without relevant 
complications. A randomized trial on post-cardiac sur-
gery patients with hyperuricemia showed that febux-
ostat had superior anti-inflammatory and renoprotective 
effects than allopurinol [27]. In experimental studies, XO 
inhibition by febuxostat reduced the production of reac-
tive oxygen species (ROS) to a greater extent than allopu-
rinol and attenuated experimental atherosclerosis in mice 
[28–30]. However, there is only limited evidence on the 
effect of pharmacological intervention on carotid athero-
sclerosis in patients with hyperuricemia.
The PRIZE study was designed with the aim to evalu-
ate the effects of febuxostat on atherosclerosis in patients 
with hyperuricemia by measuring changes in carotid 
intima-media thickness (IMT), a marker of atherosclero-
sis. This study will be the first to provide clinical evidence 
as to whether or not an anti-hyperuricemic agent, febux-
ostat, can suppress carotid atherosclerosis.
Methods
Study overview and design
The PRIZE study is a multicenter, prospective, rand-
omized, open-label, blinded-endpoint (PROBE) clinical 
trial that is being carried out in Japan. The study aims to 
test the hypothesis that febuxostat treatment is superior 
to non-pharmacological treatment for hyperuricemia to 
prevent progression of carotid atherosclerosis, measured 
as IMT, after 24 months of treatment. Eligible patients are 
assigned randomly (ratio 1:1) to either a febuxostat group 
(10–60 mg/day) or a control group (non-pharmacological 
treatment). Because the usual daily dosage of febuxostat 
is 10–60 mg in Japan, participants assigned to the febux-
ostat group receive an initial dose of 10 mg/day that can 
be subsequently increased to 60  mg/day to achieve an 
appropriate UA level. The study protocol states that all the 
patients will be followed up annually for 24 months.
Prior to initiation, the study protocol was approved by 
the local institutional review board and independent eth-
ics committee at every site. The trial will be conducted 
in full compliance with the Declaration of Helsinki and 
according to the Ethical Guidelines for Medical and 
Health Research Involving Human Subjects established 
by the Ministry of Health, Labour, and Welfare and 
Ministry of Education, Culture, Sports, Science, and 
Technology.
Trial Registration Unique trial Number, UMIN000012911 (https://upload.umin.ac.jp/cgi‑open‑bin/ctr/ctr.cgi?function=
brows&action=brows&type=summary&recptno=R000015081&language=E)
Keywords: Carotid artery, Febuxostat, Hyperuricemia, Intima‑media thickness (IMT), Randomized controlled trial, 
Xanthine oxidase inhibitor
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Study population
A total of 500 patients with hyperuricemia are scheduled 
to be enrolled between 2014 and 2016 and then followed-
up for 24 months. Prior to assessment of eligibility, every 
patient is required to receive an adequate explanation 
of the study plan, with written informed consent then 
obtained from each patient. The inclusion and exclu-
sion criteria for the study are listed in Table  1. In brief, 
these criteria include: eligible patients aged ≥20  years 
with asymptomatic hyperuricemia (UA >7.0  mg/dL) 
and a maximum carotid IMT ≥1.1  mm. A UA level of 
7.0  mg/dL is defined as the minimal level for diagnos-
ing hyperuricemia in Japan, with medical intervention in 
such patients being considered valid [31]. Patients who 
have received any UA-lowering agents within the 8-week 
period prior to enrollment are not enrolled in the study.
Randomization
Randomization takes place following an initial ultrasono-
graphic estimation of carotid IMT at the PRIZE Data 
Center. Randomization is performed using a modified 
minimization method with a biased-coin assignment 
balanced for age (<65, ≥65  years), gender, presence or 
absence of type 2 DM, UA (<8, ≥8  %), and maximum 
IMT (<1.3, ≥1.3 mm). Random allocation incorporating 
a stratified technique is generated automatically using a 
minimization method on a computer program [32].
Treatment outline
All participants in both groups need to receive and con-
tinue an appropriate diet (Fig.  1) and exercise therapy 
for hyperuricemia, using the treatment brochure for the 
current study modified from the treatment guideline 
[31]. Patients assigned to the febuxostat group receive 
an initial dose of 10 mg/day that is increased to 20 mg/
day at 1 month and 40 mg/day at 2 months. Febuxostat 
40  mg daily is the principle maintenance dosage up to 
24 months, but at 12 months or later the dose of febux-
ostat is increased to 60 mg/day, if possible. If UA levels 
decrease to ≤2.0 mg/dL during the study period, the next 
incremental step of febuxostat dose will not be needed 
and the dose is decreased to the preceding step. On 
the other hand, if the UA level is >12.0 mg/dL or gouty 
arthritis develops as an adverse event, the investigators 
must discontinue the study treatment and initiate appro-
priate procedures and treatments. The details of the dis-
continuance criteria are listed in Table 2. Drugs that must 
not be used are allopurinol, benzbromarone, probenecid, 
bucolome, and topiroxostat in both groups, and febux-
ostat in the control group. The participant’s background 
Table 1 Detailed inclusion and exclusion criteria
ALT alanine aminotransferase, AST aspartate transaminase, CAS carotid artery stenting, CEA carotid endarterectomy, eGFR estimated glomerular filtration rate, IMT 
intima-media thickness, NYHA New York Heart Association, UA uric acid
Inclusion Exclusion
Adults (aged ≥20 years)
Patients with asymptomatic hyperuricemia with a serum UA >7.0 mg/dL
Patients with a maximum IMT ≥1.1 mm
The patient provided written informed consent to participate in the study
Patients being treated with any of the following antihyperuricemic agents 
within 8 weeks before confirmation of the eligibility criteria: allopurinol, 
benzbromarone, probenecid, bucolome, topiroxostat, or febuxostat
Patients being treated with any of the following agents at the time of con‑
firmation of the eligibility criteria: mercaptopurine hydrate, azathioprine, 
vidarabine, or didanosine
Patients who have undergone an operation or who have severe infections 
or serious injury at the time of confirmation of the eligibility criteria.
Patients who had a myocardial infarction, angina pectoris, percutaneous 
transluminal coronary angioplasty/bypass surgery, cerebral infarction, 
cerebral hemorrhage, subarachnoid hemorrhage, or transient cerebral 
ischemic attack within 3 months before confirmation of the eligibility 
criteria
Patients with cardiac dysfunction (NYHA class IV)
Patients with gouty tophus, or those who have subjective symptoms of 
gout arthritis within 1 year before confirmation of the eligibility criteria
Patients with a complication or a disease history (eGFR <30 mL/min/1.73 m2 
or patients on dialysis)
Patients with severe liver dysfunction (AST or ALT ≥2 times the upper limit 
of the institutional standard value)
Patients with a complication or a disease history (e.g. malignant tumor) 
who are considered not eligible for the study by the attending doctor
Patients with a history of hypersensitivity to febuxostat
Pregnant, possibly pregnant, or lactating women or those who wish to 
become pregnant during participation in the study
Patients who have undergone CEA or CAS surgery
Patients who are considered not eligible for the study by the attending 
doctor due to other reasons
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treatment, such as anti-diabetic agents, antiplatelet 
agents, anti-hypertensive agents, and lipid-lowering 
agents remains unchanged, if possible, during the study 
period, taking into account the appropriate clinical sever-
ity of the diseases. 
Measurement of carotid IMT
The initial carotid ultrasound examinations are per-
formed at each site to determine the eligibility prior to 
study inclusion and then measured at a core laboratory 
(Tsukuba University) at 0, 12, and 24  months after ran-
domization. High-resolution carotid ultrasonography 
is performed at each ultrasound laboratory using stand-
ardized imaging protocols and systems equipped with 
>7.5  MHz linear transducers. Expert trained sonogra-
phers who have attended a lecture on measuring carotid 
IMT carry out the procedure, according to the method 
recommended by the Mannheim carotid IMT consensus 
[33, 34]. Longitudinal B-mode images, perpendicular to 
the ultrasound beam, with a 3–4 cm imaging depth, are 
recorded in the distal common carotid arteries (CCA), 
bulbs, and proximal internal carotid arteries (ICA) on 
both sides. The lateral probe incidence is used to obtain 
CCA images, using external landmarks with an original 
semicircular protractor developed for this purpose. The 
mean CCA-IMT indicates the average IMT value of the 
right and left CCA-IMT, 10 mm from the bulb. The fol-
lowing far wall IMTs will be measured: maximum IMT of 
the CCA; mean and maximum IMTs of the bulb and ICA; 
and the plaque area with the lowest echogenicity and its 
median gray scale [35]. Plaque is defined as a focal region 
with an intima-media thickness ≥1.1 mm that protrudes 
into the lumen, and is distinct from the adjacent bound-
ary. The optimized R-wave gated still frames of the carotid 
IMT are stored as JPEG files, with all the parameters col-
lected and measured at the core laboratory. An expert 
analyzer unaware of the clinical information of the sub-
jects will measure all the IMT values using an automatic 
IMT measurement software program (Vascular Research 
Tools 5, Medical Imaging Applications, Iowa, USA) [36]. 
The analyzer will select the best images of the right and 
left CCA, bulb, and ICA. The software program identifies 
the lumen/intima and the media/adventitia borders in this 
region and calculates the distance between them.
Outcomes
The primary endpoint is the percentage change in mean 















40 mg (maintenance dosage)
60 mg (if possible)
Febuxostat group 
Modification of lifestyle for hyperuricemia
0 24 (months)1261 2 3
End of study
(1:1)
Fig. 1 Study outline
Table 2 Discontinuance criteria
UA uric acid
Serum UA >12.0 mg/dL
Onset of gout arthritis
Considered inappropriate to continue the study by investigators due to 
adverse side effects or serious adverse events
Needed to receive any prohibited concomitant drugs
Participant relocated or changed doctor
The participant decides they no longer wish to continue the study
Considered inappropriate to continue the study by investigators due to 
some other reason
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The secondary endpoints are as follows: (1) Ultra-
sonography parameters at baseline and, after 12 and 
24  months, expressed as the magnitude of change and 
percentage change from baseline of mean IMT, maxi-
mum IMT in the common carotid artery, bulbs, and 
internal artery, and plaque area and echogenicity. If mul-
tiple plaques are observed in a patient, a plaque with the 
lowest echogenicity at baseline will be selected for assess-
ment of plaque area and echogenicity. (2) Serum UA lev-
els at baseline, and after 6, 12, and 24 months, expressed 
as the magnitude of change and percentage change from 
baseline. (3) Levels of the following clinical parameters 
at baseline and after 6, 12, and 24 months, expressed as 
the magnitude of change and percentage change from 
baseline; serum levels of total cholesterol, low-density 
lipoprotein (LDL) cholesterol (indirect method), high-
density lipoprotein (HDL) cholesterol, triglyceride, 
non-HDL cholesterol, creatinine, estimated glomerular 
filtration rate, urinary albumin excretion (in patients with 
DM), urinary liver-type fatty acid binding protein (in 
patients with DM or chronic kidney disease). (4) Blood 
pressure levels measured at a clinic and N-terminal pro-
brain natriuretic peptide levels at baseline and after 12 
and 24  months, expressed as the magnitude of change 
and percentage change from baseline. (5) Composite 
events of cardiovascular death, non-fatal myocardial 
infarction, and stroke, renal events such as doubling of 
serum creatinine, initiation of renal replacement therapy, 
or renal transplantation, and all-cause death, expressed 
as the incidence of each event in individuals from base-
line to 24 months or at study discontinuation. (6) Adverse 
events that occurred between baseline and 24  months. 
The exploratory endpoints include values at baseline and 
after 12 and 24  months, and the magnitude of change 
and percentage change from baseline in cardiovascular-
related examinations including flow-mediated dilatation 
(FMD), pulse wave velocity (PWV), cardio-ankle vascu-
lar index (CAVI), echocardiography (systolic and dias-
tolic function, left atrial dimension, left ventricular mass 
index), and augmentation index (AI) and the following 
biomarkers: high-sensitivity C-reactive protein, 1.5AG, 
small dense LDL, remnant lipoprotein cholesterol, 
malondialdehyde-altered LDL, serum cystatin C, recep-
tor for advanced glycation end products, high-molecular 
weight adiponectin, high-sensitive troponin I, angiopoie-
tin-like protein 2, and blood pressure measured at home.
Statistical considerations
Sample size and power calculation
We assumed the percentage changes in average carotid 
IMT in the control and febuxostat groups 24  months 
after randomization in the study would be as follows:
A percentage change in average carotid IMT of 
+1.96  % at 18  months based on our previous database 
(unpublished data). We estimated the increase from 
baseline would be +2.62 % after 24 months. The stand-
ard deviation (SD) will be same as that measured in our 
previous study. We assume that the percentage change in 
average carotid IMT will be +2.6 ± 6.0 % (mean ± SD) 
in the control group. On the other hand, there is no data 
about the effect of febuxostat on carotid IMT. The effect 
of febuxostat was set conservatively at +1.0  ±  6.0  % 
based on data on pitavastatin from a previous study 
that showed an annual rate of change in carotid IMT of 
−0.8 % [37]. Based on these assumptions of a 1.6 % group 
difference in the primary endpoint at 24 months and a SD 
of 6.0 % for individual differences to achieve 90 % power 
for a two-sided, two-sample t test at the 0.05 signifi-
cance level, a sample size of 250 patients in each group 
is required. A total of 500 patients will be enrolled in the 
study in anticipation of a 10 % dropout rate.
Statistical analysis plan
The statistical analysis and reporting of this trial will be 
conducted in accordance with the CONSORT guidelines, 
with the primary analyses based on the intention-to-treat 
principle. For the baseline variables, summary statis-
tics will be calculated and expressed as frequencies and 
proportions for categorical data, and means and SD for 
continuous variables. Baseline variables will be compared 
using Fisher’s exact test for categorical outcomes and 
unpaired t-tests for continuous variables.
For the primary analysis comparing treatment effects, 
the baseline-adjusted means and their 95  % confidence 
intervals (CIs), estimated by analysis of covariance, 
were compared between treatments (febuxostat group 
vs. the control group). This will be carried out taking 
into account the variation due to treatment effects, and 
using the allocation adjustment factors as the covari-
ates. To compare the treatment groups, the differences 
in the baseline-adjusted means and associated 95 % CIs 
will be expressed as a proportion of the reference treat-
ment baseline-adjusted means. The primary analysis will 
not impute missing observations, with the mixed effects 
model for repeated measures (MMRM) being used as a 
sensitivity analysis to examine the effect of missing data. 
In addition, MMRM will be used as a sensitivity analy-
sis to examine the outcomes at months 0 and 24 modeled 
as a function of time, treatment, and treatment-by-time 
interaction. The secondary analysis will be performed in 
the same manner as the primary analysis.
All comparisons are planned, and all p values will be 
two-sided. A p value <0.05 will be considered statisti-
cally significant. All statistical analyses will be performed 
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using the SAS software program, version 9.4 (SAS Insti-
tute, Cary, NC, USA). The statistical analyses will be 
described as a priori in a statistical analysis plan.
Study oversight and organization
The PRIZE study is an investigator-initiated clinical 
trial conducted by a study organization consisting of 
the following members (Additional file 1). The principle 
investigator of the study is Koichi Node, Department of 
Cardiovascular Medicine, Saga University. A steering 
committee will be responsible for study design and sci-
entific execution. An executive committee will advise on 
planning and management of the study. An independent 
data and safety monitoring board will evaluate safety dur-
ing the study period. A clinical event committee, blinded 
to any information related to group allocation, will cen-
trally evaluate the clinical events. Carotid IMT will be 
measured at a central location, Tsukuba University. Data 
monitoring will be enforced to ensure the research is 
performed properly, with an independent audit team 
inspecting several main hospitals to ensure the quality of 
the data. Sub-study groups will analyze each exploratory 
endpoint such as FMD, PWV/CAVI, IMT, echocardiog-
raphy, and AI.
Study progress and current status
The PRIZE study was registered by the UMIN in Janu-
ary 2014 (ID: 000012911). End of recruitment period 
was initially set at January 2016; however, this has been 
extended to June 2016 due to a shortage of study partici-
pants. At present (31 March, 2016), a total of 456 patients 
have been recruited into the study.
Discussion
Although hyperuricemia is associated strongly with the 
MetS, including HT, HL, and type 2 DM, and subsequent 
risk of atherosclerosis, its significance as an independent 
risk factor for clinical outcome still remains somewhat 
controversial [16, 38]. Recently, a retrospective cohort 
study showed that patients with gout, especially women, 
had a higher risk of developing CVD after adjustment for 
vascular risk factors [39]. The prevalence of gout in US 
adults is about 3.9 %, while the prevalence of hyperurice-
mia, a precondition necessary for developing gout, is 
over 21 % [40]. It is therefore essential to prevent patients 
with asymptomatic hyperuricemia from developing gout 
by using comprehensive therapeutic strategies. Several 
studies have shown positive correlations between UA 
levels and FMD, atherosclerotic plaques, and IMT in the 
carotid artery [4, 12, 41]. The incidence of hyperuricemia 
is also high in patients with chronic heart failure and is a 
predictive factor for prognosis of the condition [42, 43]. 
Moreover, increased levels of UA cause direct damage to 
renal tissues, resulting in development of chronic kidney 
disease [44, 45], and have recently been identified as an 
independent atherogenic risk factor. There is evidence 
that excessive production of ROS via UA per sé and UA 
metabolic processes play a pivotal role in the develop-
ment of oxidative stress and the pathophysiology of ath-
erosclerosis [46, 47]. ROS promote the oxidation of lipids, 
making them more atherogenic, and also inactivate nitric 
oxide (NO). Peroxynitrite is produced by the interaction 
between NO and the radical superoxide anion, a strong 
oxidant that contributes to inactivation of proteins [47]. 
Exposure to ROS changes vascular gene expression, lead-
ing to increased inflammatory chemokine production, 
expression of adhesion molecules, and cellular prolifera-
tion and hypertrophy [48]. Despite a strong rationale for 
the important role of ROS in the development of athero-
sclerosis, there is still no clinical evidence that scavenging 
ROS prevents progression of atherosclerosis [49, 50]. A 
possible explanation for the failure of anti-oxidative ther-
apy may be due, in part, to the highly adaptive responses 
in the cellular defense system and compartmentaliza-
tion of ROS signaling. More specific and mechanistic 
approaches to affect ROS-generating systems and inhibi-
tion of vascular oxidative stress are therefore required.
XO is an enzyme responsible for catalyzing the final 
steps of the metabolic process for purines, specifically 
the conversion of hypoxanthine to xanthine and sub-
sequently to UA. The degradation of purines to UA is a 
source of ROS production that has detrimental effects on 
atherosclerosis progression. Experimental studies have 
also shown that XO binds to endothelial cells and inacti-
vates NO [51]. Based on this evidence of the physiological 
role for XO, strategies for XO inhibition are considered 
reasonable for inhibiting progression of atherosclero-
sis. However, no large randomized trials have assessed 
the effect of XO inhibitors on atherosclerosis, although 
a recent meta-analysis demonstrated that XO inhibition 
had favorable effects on endothelial function [52].
Febuxostat is a novel selective non-purine XO inhibi-
tor, which has higher affinity for both the oxidized and 
reduced forms of XO [53]. Due to mechanistic differ-
ences in action compared to conventional XO inhibi-
tors, febuxostat has a stronger inhibitory effect on XO 
[29]. Sezai et  al. [27, 54] reported that compared with 
allopurinol, febuxostat had superior anti-oxidative and 
anti-atherogenic activities, and renoprotective effect, in 
addition to a significantly greater UA-lowering effect in 
post-cardiac surgery patients with hyperuricemia. Febux-
ostat has been shown to improve endothelial function and 
suppress atherosclerotic plaque formation by reducing 
enhanced XO activity in ApoE(−/−) mice [30]. In addition, 
febuxostat was reported to contribute to cardioprotec-
tion through its anti-oxidant and anti-apoptotic effects 
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in doxorubicin-induced cardiomyopathy model rats [55]. 
The PRIZE study was designed based on these experimen-
tal evidences, and the study is considered to be important 
and meaningful for the clinical implications of febuxostat.
Accumulated evidence indicates that noninvasive 
assessment of carotid artery IMT is used widely to assess 
atherosclerosis as a surrogate marker and is associated 
strongly with an increased risk of cardiovascular disease 
[56], presence of coronary artery disease, and occur-
rence of cardiovascular events even after adjustment for 
known cardiac risk factors [57–61]. Previous studies have 
reported that UA level is an independent risk factor for 
carotid IMT in patients with hypertension or type 2 DM. 
[62, 63]. However, there is only limited evidence whether 
pharmacological intervention with a XO inhibitor 
reduces the progression of carotid IMT in patients with 
asymptomatic hyperuricemia. Recently, Liu et  al. [64] 
reported a randomized single center trial, in which 176 
patients with type 2 DM and asymptomatic hyperurice-
mia were randomized into either allopurinol or conven-
tional treatment groups. The results showed allopurinol 
not only improved insulin resistance but also reduced 
carotid IMT, compared to the conventional treatment 
group. Therefore, XO inhibitors may potentially hinder 
the progression of carotid atherosclerosis. As mentioned 
earlier, because febuxostat is more effective for inhibiting 
XO, a greater inhibitory effect on carotid IMT would also 
be expected in our study.
It is reported that the levels of UA in women are obvi-
ously lower than in men, and generally there is a stronger 
association between serum UA and cardiovascular events 
in women than in men [14, 65]. In contrast, Zhao et  al. 
[66] reported that elevated levels of UA were associated 
with increased risk of all-cause mortality in men, but not 
in women. In men without the Mets but not in men with 
the Mets, or in women with or without the Mets, the 
prevalence of carotid atherosclerosis was similarly associ-
ated with increased UA levels [4, 12]. The atherosclerosis 
risk in communities (ARIC) study, however, demonstrated 
that serum UA levels per sé might not be a risk factor for 
carotid atherosclerosis in both genders [67]. In addition, 
in the randomized clinical trials to evaluate the therapeu-
tic effect of XO inhibitors in patients with gout, gender 
specific effects of XO inhibitors were not fully evaluated 
due to the fact that the majority of participants were male 
[68–70]. Accordingly, the specific gender difference in the 
contribution of serum UA to the cardiovascular compli-
cations and mortality may be, in part, controversial, and 
the effect of febuxostat on the carotid atherosclerosis still 
remains to be determined. Because gender is set as an 
allocation factor in the prize study, the gender specific 
analyses may be able to address such clinical questions.
In conclusions, on the basis of these backgrounds, we 
have designed and initiated a randomized multicenter, 
investigator-initiated trial to test the hypothesis that 
UA-lowering treatment by the XO inhibitor, febuxostat, 
for 24 months may delay the progression of carotid IMT 
in Japanese patients with asymptomatic hyperuricemia. 
This study may provide important evidence that febux-
ostat has anti-atherosclerotic actions on carotid IMT and 
enhance the clinical significance of UA-lowering treat-
ment by febuxostat.
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